HALDRONE Drug Patent Profile

Which patents cover Haldrone, and when can generic versions of Haldrone launch?

Haldrone is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in HALDRONE is paramethasone acetate. There are two drug master file entries for this compound. Additional details are available on the paramethasone acetate profile page.

Summary for HALDRONE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	31
Patent Applications:	2,600
DailyMed Link:	HALDRONE at DailyMed

US Patents and Regulatory Information for HALDRONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	HALDRONE	paramethasone acetate	TABLET;ORAL	012772-005	Approved Prior to Jan 1, 1982		DISCN	No	No
Lilly	HALDRONE	paramethasone acetate	TABLET;ORAL	012772-006	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for HALDRONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lilly	HALDRONE	paramethasone acetate	TABLET;ORAL	012772-005	Approved Prior to Jan 1, 1982
Lilly	HALDRONE	paramethasone acetate	TABLET;ORAL	012772-006	Approved Prior to Jan 1, 1982

International Patents for HALDRONE

See the table below for patents covering HALDRONE around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	1239307	Verfahren zur Herstellung therapeutisch wirksamer Steroidverbindungen
United Kingdom	902293
Switzerland	378881	Verfahren zur Herstellung von Steroidverbindungen
United Kingdom	902292
United Kingdom	902294

HALDRONE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Drug Discovery Technologies: A Comprehensive Overview

Introduction

The drug discovery technologies market is a vibrant and rapidly evolving sector, driven by advancements in technology, increasing healthcare expenditures, and the growing need for innovative treatments. This article delves into the market dynamics, financial trajectory, and key trends shaping the future of drug discovery.

Market Size and Growth

The global drug discovery technologies market has experienced significant growth, reaching a value of nearly $66.07 billion in 2023. This market is projected to expand from $66.07 billion in 2023 to $113.01 billion by 2028, and further to $188.64 billion by 2033, with a compound annual growth rate (CAGR) of 11.3% and 10.8% respectively[1].

Segmentation of the Market

By Technology

The market is segmented into various technologies, including high throughput screening, genomics, bioinformatics, combinatorial chemistry, biochips, and bioanalytical instruments. High throughput screening was the largest segment in 2023, accounting for 25.1% of the total market. However, the genomics segment is expected to be the fastest-growing segment, with a CAGR of 13.3% during 2023-2028[1].

By Drug Type

The market is also segmented by drug type into small molecule drugs and biologic drugs. Small molecule drugs dominated the market in 2023, accounting for 70.8% of the total. However, biologic drugs are expected to grow at a CAGR of 12.5% during 2023-2028, making them the fastest-growing segment[1].

By End-User

Pharmaceutical companies were the largest end-users in 2023, accounting for 36.3% of the market. Biopharmaceutical companies are expected to be the fastest-growing segment, with a CAGR of 13.2% during 2023-2028[1].

By Disease Application

The market is segmented by disease application into cancer diseases, immunological diseases, neurological diseases, cardiovascular diseases, and others. Cancer diseases were the largest segment in 2023, accounting for 33.8% of the total market, and are expected to continue growing at a CAGR of 12.5% during 2023-2028[1].

Regional Dynamics

North America was the largest region in the drug discovery technologies market in 2023, accounting for 40.5% of the total market. Asia-Pacific and North America are expected to be the fastest-growing regions, with CAGRs of 12.2% and 11.6% respectively[1].

Drivers of Growth

Several factors are driving the growth of the drug discovery technologies market:

• Increased Pharmaceutical R&D Expenditure: Higher investments in research and development have accelerated drug discovery.
• Demand for Personalized Medicine: The growing demand for personalized treatments has fueled the adoption of advanced technologies.
• Favorable Government Initiatives: Government support and initiatives have played a crucial role in accelerating drug discovery research[1].
• Aging Population and Rising Healthcare Expenditure: The increasing global aging population and rising healthcare expenditures are driving the need for new and effective treatments[1].

Challenges

Despite the growth, the market faces several challenges:

• Complex and Time-Consuming Regulatory Approval Processes: These processes can significantly delay the introduction of new drugs to the market.
• High Cost of Drug Discovery: The average cost of bringing a new drug to market is about $2.6 billion, with a development timeline spanning 10 to 15 years[3].

Market Trends

Advanced Technologies

The focus on advanced technologies such as AI, genomics, and bioinformatics is accelerating drug development. For instance, the introduction of intelligent robotics labs to expand AI-driven drug discovery efforts is a significant trend[1].

Strategic Partnerships and Collaborations

Major players are leveraging strategic collaborations to enhance drug discovery and accelerate the development of novel therapeutics. These partnerships are crucial for advancing healthcare innovation and expanding access to advanced diagnostic technologies[1].

First-to-Market Advantage

Being the first to market can offer a significant advantage, especially in the case of injectable drugs. However, late movers can also succeed if they expand indications faster than early entrants[4].

Financial Landscape

The financial landscape of the pharmaceutical sector is complex and challenging:

• High Development Costs: The average cost of bringing a new drug to market is substantial, and the probability of success is low, around 10% for drugs entering clinical trials[3].
• Declining ROI: The return on investment (ROI) for pharmaceutical R&D has been declining, with a forecasted ROI of just 1.2% in 2022, down from 1.9% in 2021[3].

Key Players

The market is dominated by several major players, including AstraZeneca, Merck, and GlaxoSmithKline. These companies are investing heavily in advanced technologies and strategic collaborations to maintain their market position[1].

Future Outlook

The future of the drug discovery technologies market looks promising, driven by:

• Escalating Global Burden of Chronic Diseases: The increasing incidence of chronic diseases is fueling the demand for new treatments, projected to drive the pharmaceutical market revenue to exceed $1.4 trillion by 2028[3].
• Advancements in Technology: Continued advancements in AI, genomics, and other technologies will accelerate drug discovery and development.

"The pharmaceutical market revenue in 2024 is projected to be 1.15 trillion dollars, and it is forecasted to exceed 1.4 trillion by 2028. This exponential growth is primarily fueled by the escalating global burden of chronic diseases."[3]

Conclusion

The drug discovery technologies market is poised for significant growth, driven by technological advancements, increasing healthcare expenditures, and the growing need for innovative treatments. Despite challenges such as high development costs and complex regulatory processes, the market is expected to expand substantially over the next decade.

Key Takeaways

• The global drug discovery technologies market is projected to reach $188.64 billion by 2033.
• Advanced technologies like genomics and AI are driving growth.
• Strategic partnerships and collaborations are crucial for market success.
• The high cost of drug discovery and declining ROI are significant challenges.
• The market is segmented by technology, drug type, end-user, and disease application.
• North America and Asia-Pacific are expected to be the fastest-growing regions.

FAQs

Q: What is the current size of the global drug discovery technologies market? A: The global drug discovery technologies market reached a value of nearly $66.07 billion in 2023[1].

Q: What is the expected growth rate of the drug discovery technologies market? A: The market is expected to grow at a CAGR of 11.3% from 2023 to 2028 and 10.8% from 2028 to 2033[1].

Q: Which segment is expected to be the fastest-growing in the drug discovery technologies market by technology? A: The genomics segment is expected to be the fastest-growing segment, with a CAGR of 13.3% during 2023-2028[1].

Q: What are the main drivers of growth in the drug discovery technologies market? A: Increased pharmaceutical R&D expenditure, demand for personalized medicine, and favorable government initiatives are key drivers[1].

Q: What is the average cost of bringing a new drug to market? A: The average cost of bringing a new drug to market is about $2.6 billion, with a development timeline spanning 10 to 15 years[3].

Sources

1. Global Drug Discovery Technologies Market Insights - GlobeNewswire
2. Diversified Revenue Stream Can Weather The Storm - Seeking Alpha
3. Investment Trends in Pharmaceutical Research - DrugBank Blog
4. Pharma's first-to-market advantage - McKinsey & Company
5. Rethinking the financial network - Bank for International Settlements